



European CRO Federation

"Ethical considerations for paediatric trials - how can Ethics Committees in the European Member States and the Paediatric Committee at the European Medicines Agency work together?" "Industry experience with ethical review of paediatric trials" Result of survey by EUCROF

29-30 November 2011, EMA, London

Dr. Martine Dehlinger-Kremer Vice President Global Regulatory Affairs, RPS Inc. Lead of Paediatric Working Group of EUCROF





Introduction and Background Information


- Experience with Ethical Review of Paediatric Trials; EUCROF Survey
 - Survey results
 - Individual Cases Studies





Number of Paediatric Studies in EEA

Number of paediatric studies have increased from 2005 to 2010 >600 studies in 2005 to 949 studies in 2010





EUCROF SURVEY



"Industry experience with ethical review of paediatric trials" – EUCROF Survey Results

Data collected

- Collected between September October 2011
- Were consulted
 - All European countries through EUCROF (11 CRO Associations, approx. 300 CROs)
 - 3 Peadiatric Networks (France and Germany)

Data received

15 Responses: Case Studies, from CROs only



"Industry experience with ethical review of paediatric trials" – EUCROF Survey Results

Countries involved in the studies

 Austria, Belgium, Bulgaria, Denmark, Finland, Germany, Italy, Netherlands, Norway, Poland, Spain, Sweden & UK

Studies overview

- Studies performed between 2008 and 2011: 2008 (1), 2009 (5), 2010 (5), 2011 (4)
- 14 multinational studies, 1 national study
- 1 phase I, 5 phase II, 9 phase III



Case studies - Concerns from Ethic Committees

Concerns from the Ethic Committees

 In 14 out of 15 studies

Concerns nature

- Child protection
- Study procedure
- Study design
- Others



Ш

Concerns from Ethic Committees

Child protection

- Request change to ICF & provide assent per age group (8/15)
- Burden for participants, impact schooling (1/15)
- Exclusion of mentally disabled minors (1/15)
- Contraception (2/15)

Study procedure

- Blood volume collection, Number of Vena punctures (3/15)
- Invasive procedures (2/15)



Concerns from Ethic Committees

Study design

- Benefit of study to paediatric subject (2/15)
- Product already approved in adolescent (1/15)
- Clarifications on the sample size calculation (1/15)
- Inclusion new groups in extension study (1/15)
- Evaluation strategy, subgroup analysis (1/15)
- Use of placebo questioned (1/15)

Others

1/15

- Qualification of investigator & paediatric experience (1/15)
- Insurance coverage (1/15)

EC with no concern



Outcome from the EC reviews

13 out of 15 studies approved

2 studies withdrawn by the applicants

- Issues could not be solved
- Delay for the multinational study

2 months in average to resolution of the issue (1-5 months)




Ш



INDIVIDUAL CASE STUDIES



A Multicenter, Double-blind, Randomized, Placebo-controlled, **4-Armed Parallel Group Study to Evaluate the Efficacy of XX** 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute **Migraine Headache in Adolescents - QUESTION**



Concerns expressed by the Ethic Committee

- Use of placebo
- As per the EC the placebo effect can be assessed by treating two attacks, in which case every subject can receive placebo and active medication, instead using placebo during the screening period and in the placebocontrolled 4-armed parallel group
- The ICF remains vague on the use of placebo in part l

A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of XX 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents - RESOLUTION

Actions undertaken to obtain resolution

- Requested support from Finnish PDCO member: no response
- Discussion between PI and ECs chairman which reviewed the study

Applicant explanations

- A change in study design was not possible as the design was agreed by FDA. The protocol was approved by many other EU National Authorities and Ethics Committees. As such the request from Finland was considered contradictory to the concept of multinational trial and to the spirit of the Paediatric Regulation
- For an unbiased /blind assessment of the potential pain relief the subject needs to be unaware of the true nature of the drug he received. ICF wording was revised and included that the first dose was for practise with a technically identical device. On the second visit, those subject with a placebo response will be excluded.

Time required to solve the issue: 5 months



A Multicenter, Double-blind, Randomized, Placebo-controlled, **4-Armed Parallel Group Study to Evaluate the Efficacy of XX** 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute **Migraine Headache in Adolescents**

> Phase III Study, Multinational, 2011, Neurology / Migraine

Children 11-17 years old

Ethic Committee: Germany. Submission March 2011


Concerns expressed by the Ethic Committee

• EC rejected the study on the ground that XX is already approved at a dosage of 5 mg for the treatment of adolescents



A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of XX 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute **Migraine Headache in Adolescents - RESOLUTION**





- Request is contradictory to the concept of multinational trial and the spirit of the Paediatric Regulation
- The 4 parallel groups design will allow defining which one of the 3 different doses is the most effective compared to placebo. One cannot know that the 0.5 mg dose is probably ineffective before it has been properly tested
- Contacted German PDCO member who was supportive but could not overrule EC decision
- PI meet the EC chairman who confirmed that the EC will not give an approval for the study. BfArM approved the study. EC expressed that they are not dependent on BfArM decision

Germany

Time required to solve the issue: 2 months Final outcome: Sponsor withdraw application in




A Multicenter, Double-Blind, Parallel-group Study to Evaluate Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1-to-11-Year-Old Paediatric Subjects With Endoscopically Proven GERD

Phase III Study , Multinational, 2009, Gastro- enterology

Children 1- 11 years old

> Ethic Committee: Bulgaria. Submission December 2009



Concerns expressed by the Ethic Committee

- Negative opinion from EC
- Multiple invasive procedures, in total 3 EGD with biopsies, which is considered unjustified with respect to subject safety
- The EC considered there is inappropriate decision and confusion between standard of care and study requirement
- Lack of specialization of the proposed Principal Investigators in paediatric gastroenterology



Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1-to-11-Year-Old Pediatric Subjects With Endoscopically Proven GERD. RESOLUTION

Actions undertaken to obtain resolution

- Applicant decided not to Appeal decision of Central Ethics Committee due to the delay it would have created to have this country included in multinational study
- > Amend the Protocols as per EC request was not acceptable for a multinational trial, which had been approved in all other countries and by those ECs
- The PI lack of specialization in pediatric gastroenterology could have been endorsed, although the most important was experience in performing EGD & biopsies
- > Time required to solve the issue: NA


Outcome:

Bulgaria did not participate in the study





Allergy – Allergic Rhinitis & Chronic Urticaria






Allergy – Allergic Rhinitis & Chronic Urticaria


Actions undertaken to obtain







Conclusion



Conclusion



Limited number of cases received

 Reflects a yet limited experience in Paediatric Clinical Studies performed under a PIP, at least as conducted by CROs No cases from Paediatric Networks



Acknowledgments



- **EUCROF, EU CRO Federation, Roma, Italy**
- EUCROF Paediatric Working Group
- Amparo Alemany Pozuelo, TFS, Madrid, Spain



Dr. Martine Dehlinger-Kremer

Vice President, Global Regulatory Affairs, RPS Inc. Lead Paediatric Working Group EUCROF

Eucrof email: martine.dehlinger@eucrof.eu Web: <u>www.eucrof.eu</u> RPS email: <u>mdehlingerkremer@rpsweb.com</u> Web: <u>http://www.rpsweb.com</u>





Let us perform high quality Paediatric Studies and improve Health for Children



THANK YOU FOR YOUR ATTENTION!

